Temporal Course of Vessel Healing and Neoatherosclerosis After DES Implantation  by Kozuki, Amane et al.
Le
ft 
A
tr
ia
l V
o
lu
m
e 
(m
l/m
2 )
IPAH PH-HFpEF No PH
0
20
40
60
80
100
120
p < 0.0001
Figure 1. LAV Was Signiﬁcantly Lower in IPAH Than in PH-HFpEF
Only 1 idiopathic pulmonary arterial hypertension (IPAH) patient had a left
atrial volume (LAV) >43 ml/m2. Dotted pink line represents the LAV threshold
of 43 ml/m2. PH ¼ pulmonary hypertension; PH-HFpEF ¼ pulmonary hyper-
tension due to heart failure with preserved ejection fraction.
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1121are expensive, potentially dangerous, and current guidelines
recommend their use in IPAH, but not in PH-HFpEF, where they
are harmful (2).
In HFpEF, there is preserved LV systolic function, but impaired
diastolic function with abnormal LV relaxation and increased LV
ﬁlling pressure. Sustained elevations of LV diastolic ﬁlling pressures
will result in enlargement of the thin-walled left atrium, allowing
LAV to be used as a marker of the severity and chronicity of dia-
stolic dysfunction (4). Thenappan et al. (1) noted echocardiographic
left atrial enlargement in 64% of their PH-HFpEF group and only
18% of the PAH group, but they used multiple variables requiring
clinical, hemodynamic, and echocardiographic data to distinguish
between these conditions.
We acknowledge that echocardiography will give a measure of
LAV, but note the following limitations: 1) echocardiography un-
derestimates CMR-derived LAV, in both healthy subjects and pa-
tients with cardiovascular disease; and 2) CMR can be used when
acoustic windows are poor (3). We have shown that a single,
noninvasive, CMR-derived variable, LAV of <43 ml/m2, will
distinguish IPAH from PH-HFpEF, which is attractive for busy
pulmonary vascular centers.
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Temporal Course of Vessel
Healing and Neoatherosclerosis
After DES Implantation
Recently, late drug-eluting stent (DES) failure has become a po-
tential cause for concern following ﬁrst-generation DES implanta-
tion. Although these phenomena may result from multiple etiologic
factors, emerging evidence consistently suggests the importance of
delayed arterial healing and neoatherosclerosis progression as major
contributors. In vivo assessment of long-term vessel healing after
sirolimus-eluting stent (SES) deployment is limited, and the inci-
dence and process of in-stent atheroma formation remain unknown.
Although SES is no longer used in our clinical practice, many
patients have already undergone SES implantation, and a clear un-
derstanding of the long-term status of vessel reaction after stenting is
of clinical importance. Hence, this optical coherence tomography
(OCT) examination focusing on features inside the SES was per-
formed to elucidate neointimal changes during an extended period
(5 years) by comparing mid-phase and late-phase OCT ﬁndings.
From the Kobe University Hospital OCT database, 87 patients
underwent mid-phase (3 to 12 months) coronary angiography and
OCT examination after SES (Cypher, Cordis Corp., Miami Lakes,
Florida) implantation between October 2004 and January 2008. The
patients with target lesion revascularization before late-phase follow-
up were excluded from this study.
Quantitative OCT measurements were done as previously re-
ported (1). Peri-strut low intensity area (PLIA) was deﬁned as the
region around stent struts with a homogeneous lower intensity
compared with the surrounding areas, without signiﬁcant attenuation
(1). Extra-stent lumen was deﬁned as an external lumen behind the
stent struts (2). Intrastent thrombus was deﬁned as a mass protruding
beyond the stent strut into the lumen with signiﬁcant attenuation
behind the mass. Atherogenic neointima (AN) was deﬁned as neo-
intima containing a diffuse border and signal-poor region with
invisible struts underneath due to the marked signal attenuation.
The late-phase (36 to 80 months) follow-up was performed in
62 stents from 46 patients (66.9  7.8 years of age; 85% male).
Percentages of patients with hypertension, dyslipidemia, and dia-
betes mellitus were 96%, 87%, and 61%, respectively. A total of
912 matched OCT cross-sections were analyzed. Median neo-
intimal thickness increased from 82.5 mm (interquartile range
[IQR]: 65 to 117 mm) to 120.7 mm (IQR: 87 to 167 mm; p ¼ 0.006).
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1122The percentage of uncovered and malapposed struts decreased
signiﬁcantly from the mid- to late-phase follow-up.
The percentage of struts with PLIA, the frequencies of intrastent
thrombus, and extra-stent lumen decreased signiﬁcantly during the
follow-up period. The incidence of AN was 3.1% (2 stents) at the
mid-phase and 23.4% (15 stents) at the late-phase follow-up with
signiﬁcant increases (p < 0.0001) (Fig. 1).
Recently, Kim et al. (3) reported the improvement of stent
coverage and progression of in-stent neoatherosclerosis from the
observation of 9-month to 2-year serial OCT follow-up. The
present study expanded those ﬁndings to 5 years with additional
data that the frequencies of malapposed struts, PLIA, and intrastent
thrombus decreased dramatically during follow-up.
Pathologic examination of human specimens suggests that so-
called delayed arterial healing is associated with late stent
thrombosis. Delayed arterial healing is characterized by the presence
of exposed stent struts and ﬁbrin or thrombus deposition with
inﬂammatory cell inﬁltration, therefore several in vivo OCT ﬁndings,
such as uncovered struts, malapposed struts, and PLIA, can function
as surrogate markers of these phenomena. Among those, a recent
OCT report showed a strong association between OCT-detectedFigure 1. Representative OCT Images and Analyzed Data
(A) Representative optical coherence tomography (OCT) images. White arrows indi
intensity area (d), extra-stent lumen (e), intrastent thrombus (f), and atherogenic ne
arrows) at the late phase. (C) Change in OCT parameters from the mid- to late-phase
mid- and late-phase OCT examinations. (D) Change in OCT parameters from the m
thrombus, atherogenic neointima, and strut with peri-strut low intensity area betwuncovered stent struts and late stent thrombosis (4). In the present
study, the frequency of covered struts increased to 99.1%.
Nakazawa et al. (5) reported a high incidence of neo-
atherosclerosis in the neointima of DES compared with bare-metal
stents based on pathology. The high frequency of the neo-
atherosclerosis of neointima has been reported in lesions with DES
and late-phase bare-metal stents, which required repeat revascular-
ization. Here, we expanded these ﬁndings by assessing the incidence
of neoatherosclerotic changes within event-free SES. AN was
observed at both mid- and late-phase examinations, but it was
signiﬁcantly increased at the late-phase follow-up.
An important limitation of the present study is the exclusion of
patients with adverse events prior to late OCT follow-up. The
present results thus apply to AN in SES not sufﬁciently severe to
cause restenosis or stent thrombosis.
Although speculative, a variety of factors, such as the presence of
traditional coronary risk factors, responsiveness to antiplatelet ther-
apy, and shear stress distribution within the stent, can theoretically
affect the development of AN. Our results may suggest a potential
benign nature of late neoatherosclerosis, however, close observation
of these cases should be continued because the natural course ofcated covered strut (a), uncovered strut (b), malapposed strut (c), peri-strut low
ointima (g). (B) Representative case of atherogenic neointima formation (yellow
. Comparison of percentage of uncovered struts and malapposed struts between
id- to late-phase. Comparison of the stent with extra-stent lumen, intrastent
een mid- and late-phase OCT examinations.
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1123neoatherosclerosis after detection remains unclear. A longer-term
follow-up study with larger sample size will be warranted to further
address the natural course and the clinical impact of AN.
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